Budesonide / formoterol in treatment of exacerbations of COPD
Study identifier:SD-039-0698
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Effects of high dose inhaled budesonide+ formoterol versus placebo and oral prednisolone on biomarkers of airway inflammation in the treatment of exacerbations in non-hospitalised patients with mild to moderate COPD.
Medical condition
Chronic obstructive pulmonary disease (COPD)
Phase
Phase 2
Healthy volunteers
No
Study drug
budesonide/formoterol, 2x 200/6 microgram. 4 times daily, prednisolone, 30 mg once daily and placebo
Sex
All
Actual Enrollment
120
Study type
Interventional
Age
40 Years +
Date
Study Start Date: 01 Jan 2001
Primary Completion Date: -
Study Completion Date: 01 Jan 2005
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Netherlands Medical Director
AstraZeneca
